What was filed
Vimta Labs Limited released its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company describes itself as a contract research and testing organisation serving food, agri, bio/pharmaceutical, medical device, speciality chemical and electronics customers.
The company attributed the quarter's growth to its Pharmaceutical Research and Testing Services business, which it said recorded healthy traction. Sequentially, total income was near-flat against the March quarter, so the year-on-year improvement reflects the comparison against the prior-year period rather than fresh quarter-on-quarter momentum.
Divisional divergence and a new capability
Management flagged a split between its two main areas. The Pharmaceutical Research and Testing Services business saw healthy traction, while the Food Testing division continued to face what the company called ongoing global uncertainties. Vimta said the food business is progressively offsetting these headwinds through deeper domestic market penetration.
Two operational developments were noted for the quarter: the company said it completed a regulatory audit from Ukraine, and it commenced operations in Biologics contract research and development services (CRADS), which it described as an important addition to its capabilities.
Margin picture
The company reported EBITDA margin and PAT margin for the quarter that were modestly below the immediately preceding March quarter, per the filing, while remaining broadly in line with the year-ago quarter. On the company's own framing, this points to steady profitability rather than a step-change in either direction.